30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Vericel Reports 2Q16 Orthobiologic Revenue -

Vericel (VCEL) posted 2Q16 Carticel revenue of US $9.0MM, -1.1% vs. 2Q15, as reported. Carticel is an autologous chondrocyte implant marketed in the U.S. for the treatment of knee cartilage defects.

An anticipated downtime for Carticel's cleanrooms, due to the replacement of a rooftop air handler, resulted in an ~16% reduction in product shipment dates in 2Q. The cleanrooms were validated and back online in accordance with timelines, and leadership noted the hightest level of Caricel implants in June in the past four years.

During 2Q, VCEL entered into a collaboration with Dohmen Life Science, a provider of patient and reimbursement services for specialty biologics. Dohmen will provide patient support services and payor contracting/product reimbursement for Carticel and also for the MACI Autologous Cultured Chondrocyte implant, if approved, under a fee-per-service structure.

This is a transition from the previous exclusive distributor structure that was inherited with the acquisition of Carticel

Sources: Vericel Corporation, ORTHOWORLD Inc.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.